LaminarForge

Research context

Open HSV-2 research tooling starts with reproducible test units.

LaminarForge is building public context around HSV-2 latency, AAV delivery screening, tissue-on-chip workflows, and the first 16-slot cassette concept. This is nonclinical research infrastructure, not a cure claim, treatment, diagnostic product, or wet-lab protocol.

Why this exists

HSV-2 is manageable for many people, but the cure problem is still real.

HSV
Simple disease mapExposure moves through skin or mucosal cells, sensory nerve endings, and into sensory ganglia where HSV-2 can become latent. Visible symptoms can come and go, but the latent reservoir is the hard cure problem.
MEDS
Current antivirals are useful but incompleteValacyclovir and related medicines can reduce outbreaks, shedding, and transmission risk. They do not remove latent viral DNA from nerve cells.
AAV delivery

The delivery shell matters before any payload claim matters.

Known fieldOrgan-on-chip is realReusable cassettes, perfused plates, modular fluidics, and AAV-on-chip studies already exist. LaminarForge is not claiming to invent the category.
Open gapThe workflow is still hard to accessMany systems are expensive, proprietary, quote-only, or locked to vendor consumables. The public path from CAD to repeatable validation is often missing.
LaminarForge aimMake the test unit reproducibleThe first target is an open 16-slot cassette workflow: one AAV condition across a cell-type/readout panel, then scale by running matched cassettes.
16-slot cassette

One cassette is one AAV condition across a cell panel.

The cassette is not just a tray. It is the proposed repeatable unit for comparing delivery behavior across matched cell types, cell states, or readouts.

Scale comes from running more matched cassettes: candidate A, candidate B, candidate C, and so on. The goal is not to out-hype existing organ-chip systems. The goal is to make a cheaper, open, inspectable workflow that can be improved in public.

Cell 1Cell 2Cell 3Cell 4Cell 5Cell 6Cell 7Cell 8Cell 9Cell 10Cell 11Cell 12Cell 13Cell 14Cell 15Cell 16
Validation first

Cells are not software containers.

01Explain HSV-2 latency clearlyHSV-2 can establish latency in sensory nerve cells. Current antivirals reduce outbreaks, shedding, and transmission risk, but they do not remove the latent reservoir.
02Track delivery selectivityAAV capsids are delivery shells. If future therapies need to reach specific cell types, capsid behavior across relevant cell models needs to be measurable.
03Build a cell-panel cassetteOne cassette represents one AAV condition. The 16 slots hold matched cell types, states, or readouts under the same exposure.
04Validate before biology claimsNo-cell and media-only checks come first: fit, leaks, bubbles, flow balance, environmental logging, imaging access, and run records.
Source trail

Adjacent work to inspect first.

Multiplex viral tropism assay

AAV serotypes across complex human organoid cell populations with single-cell readouts.

Multi-trait AAV capsid engineering

Large capsid libraries and computational screening for delivery traits.

Reusable MPS cassette

Reusable clamped cassette and replaceable inserts for perfused microphysiological systems.

Fluidic circuit board

Modular operation of microfluidic chips for parallel cell culture and liquid dosing.

Emulate AAV organ-chip example

Commercial organ-chip framing for AAV transduction and toxicity work.

AKITA scalable organ-on-chip platform

Plate-format organ-on-chip platform with standardized layout and TEER readouts.